Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 1.25 B
The data is delayed by 15 minutes.
Description: Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company?s product candidates include FP-1039/GSK3052230, a protein therapeutic, which is in Phase 1b clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, a Phase 1 clinical trial stage antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC; Glaxo Group Limited; GSK-HGS; Pfizer Inc.; and UCB Pharma S.A. The company was founded in 2001 and is headquartered in South San Francisco, California.
|Shares Outstanding||28.2 M||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-13.93%||Sales Growth - Q/Q||-7.71%||P/E|
|P/E To EPS Growth||P/S||62.54||P/BV||8.07||Price/Cash Per Share||5.75|
|Price/Free Cash Flow||91.69||ROA||-17.73%||ROE||-25.73%||ROI|
|Current Ratio||11.41||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.12|
|Gross Margin||Operating Margin||-200.57%||Net Profit Margin||-199.36%||Dividend Payout Ratio|
|Cash From Financing Activities||79.58 M||Cash From Investing Activities||-69.81 M||Cash From Operating Activities||-10.55 M||Gross Profit|
|Net Profit||-11.04 M||Operating Profit||-11.14 M||Total Assets||224.57 M||Total Current Assets||220.33 M|
|Total Current Liabilities||19.31 M||Total Debt||Total Liabilities||69.8 M||Total Revenue||4.29 M|
|High 52 week||14.39||Low 52 week||3.64||Last close||4.13||Last change||0.98%|
|RSI||38.41||Average true range||0.37||Beta||1.41||Volume||214.71 K|
|Simple moving average 20 days||-4.79%||Simple moving average 50 days||-19.31%||Simple moving average 200 days||-51.47%|
|Performance Week||11.92%||Performance Month||-27.03%||Performance Quart||-24.64%||Performance Half||-67.12%|
|Performance Year||-68.47%||Performance Year-to-date||-55.59%||Volatility daily||5.62%||Volatility weekly||12.57%|
|Volatility monthly||25.77%||Volatility yearly||89.27%||Relative Volume||286.4%||Average Volume||344.11 K|
|New High||New Low|
2020-05-15 09:37:01 | Is Five Prime Therapeutics FPRX Stock a Solid Choice Right Now?
2020-05-08 22:37:13 | Edited Transcript of FPRX earnings conference call or presentation 7-May-20 8:30pm GMT
2020-05-07 16:05:00 | Five Prime Therapeutics Reports First Quarter 2020 Results
2020-04-22 16:05:00 | Five Prime Therapeutics Changes 2020 Annual Meeting to Virtual Format
2020-04-14 09:00:00 | Five Prime Therapeutics Appoints Tom Civik as Chief Executive Officer
2020-04-09 07:35:33 | Here's Why Five Prime Therapeutics NASDAQ:FPRX Must Use Its Cash Wisely
2020-03-18 23:04:59 | Edited Transcript of FPRX earnings conference call or presentation 27-Feb-20 9:30pm GMT
2020-02-27 17:45:10 | Five Prime Therapeutics FPRX Reports Q4 Loss, Misses Revenue Estimates
2020-02-25 16:22:00 | Five Prime Therapeutics to Present at Upcoming Healthcare Conference
2019-12-27 14:26:59 | Longtime biotech exec walks away from board to concentrate on startup
2019-12-20 13:54:34 | Head of big South San Francisco biotech thriving in first CEO role
2019-12-10 11:14:20 | Is Five Prime Therapeutics Inc FPRX A Good Stock To Buy ?
2019-11-12 14:22:56 | Edited Transcript of FPRX earnings conference call or presentation 6-Nov-19 9:30pm GMT
2019-11-08 13:02:40 | Insiders Roundup: Crocs, OPKO Health
2019-11-06 18:45:11 | Five Prime Therapeutics FPRX Reports Q3 Loss, Misses Revenue Estimates
2019-11-06 16:05:00 | Five Prime Therapeutics Reports Third Quarter 2019 Results
2019-10-11 16:04:14 | Insiders Roundup: Facebook, American Defense Systems
2019-10-10 21:57:31 | South San Francisco biotech to cut another 70 jobs, may sublease space
2019-10-10 16:01:00 | Five Prime Announces Restructuring
2019-10-02 07:30:00 | Looking for 1,600% Returns? Biotech Has No Shortage of Analyst Optimism
2019-09-20 09:59:18 | Peninsula biotech CEO resigns in latest corner office switch
2019-09-19 16:05:00 | Five Prime Therapeutics Announces Management Transition
2019-09-19 12:18:41 | What Kind Of Shareholder Owns Most Five Prime Therapeutics, Inc. NASDAQ:FPRX Stock?
2019-08-22 19:45:00 | Five Prime Therapeutics to Present at Upcoming Healthcare Conference
2019-08-10 00:04:09 | Edited Transcript of FPRX earnings conference call or presentation 7-Aug-19 8:30pm GMT
2019-08-07 18:25:10 | Five Prime Therapeutics FPRX Reports Q2 Loss, Misses Revenue Estimates
2019-08-07 16:05:00 | Five Prime Therapeutics Reports Second Quarter 2019 Results
2019-08-01 15:06:42 | Cancer-fighting Peninsula company postpones $92 million IPO
2019-06-25 11:56:38 | Estimating The Fair Value Of Five Prime Therapeutics, Inc. NASDAQ:FPRX
2019-06-24 16:05:00 | Five Prime Therapeutics Appoints Lori Lyons-Williams to its Board of Directors
2019-06-24 13:28:03 | Is Five Prime Therapeutics Inc FPRX A Good Stock To Buy?
2019-06-18 08:50:12 | Five Prime Therapeutics FPRX Looks Good: Stock Adds 9.2% in Session
2019-06-18 08:04:07 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.
2019-06-11 08:03:05 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.
2019-06-10 08:04:58 | See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.